Along the lines of your post
@aruc6393 - here’s a thought...purely hypothetical but who knows.
As per Janssens trial - a trial of a diabetes treatment could show a reduction in disease related risk e.g. renal/kidney problems.
But what if further analysis of the same trial population was able to demonstrate particular or greater benefit for patients who are predicted to develop Chronic Kidney Disease / CKD?
That would surely make the trial result even more significant and clinically relevant. And would reinforce the benefit of the drug for the patient population who most need it.
But the key to use in day to day practice would be to know which patients were more likely to develop CKD.
We know from the last investor presentation that 1 in 3 people living with T2 diabetes will develop CKD - and we know that Promarker D helps to identify who they are.
And what if health authorities such as FDA or PBS restricted the use of said drug only if the test had been used and identified the patient as being the “1 in 3”?
Makes me wonder where this could all lead?
(20min delay)